Treatment for bk virus bladder bleeding after stem cell transplant
Part of Infections, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new treatment for BK virus-related bladder bleeding after a stem cell transplant. It aims to see if the treatment is safe and effective for people whose condition hasn't improved with standard care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You've had a stem cell transplant from a donor (allogeneic) at least 21 days ago, and you were 12 or older at the time of transplant.
- You have BK virus-associated hemorrhagic cystitis (bladder inflammation with bleeding) that hasn't improved after at least 7 days of standard hospital treatment.
- You have blood in your urine (grade 2 or higher) and high levels of BK virus in your urine (more than 10^7 copies/mL).
- Your immune system has recovered enough after transplant (measured by a blood count called ANC).
- You can reduce your steroid medication to 0.5 mg/kg/day of prednisolone (or equivalent) or less.
- You agree to use effective birth control if you or your partner can become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether specially trained immune cells (virus-specific T cells) can safely treat stubborn viral infections after a stem cell transplant. It focuses on children and young adults who have not responded to standard antiviral treatments.
This trial tests a special T-cell treatment (LB-DTK-MV) for people with virus infections (CMV, BKV, EBV) that did not get better with standard medicines. It is for patients who had a stem cell transplant or certain cancer therapies like CAR-T or bispecific antibodies.
This early-phase study tests whether immune cells made from a donor (T cells) can treat BK virus infection in people whose immune system is weak after a stem cell transplant or chemotherapy. It may help control the virus causing bladder/urinary symptoms.
This Phase 1/2 study tests lab-made immune cells that specifically target BK virus in people whose BK infection keeps coming back or doesn’t improve. It may help by boosting the body’s ability to clear the virus, especially when standard antiviral treatments don’t work or can’t be tolerated.
This study tests a new, unlicensed medicine (AIC468) to see if it can reduce BK virus levels in kidney transplant patients. BK virus can sometimes harm the new kidney, so this treatment aims to lower the virus and protect the transplant.
This Phase 3 trial tests IVIG (an antibody medicine given through a vein) to treat BK virus infection after kidney or pancreas-kidney transplant. It may help lower the BK virus in the blood and protect the transplanted kidney.
Hear when a new Hemorrhagic Cystitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.